CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

COMPLETED

Taipei Medical University Hospital, Taipei

NOT_YET_RECRUITING

Gettysburg Cancer Center, Gettysburg

RECRUITING

Lombardi Comprehensive Cancer Center, Washington D.C.

RECRUITING

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

RECRUITING

Duke Cancer Center, Duke University Medical Center, Durham

NOT_YET_RECRUITING

University Cancer & Blood Center (QCCA), Athens

NOT_YET_RECRUITING

CSNF Cancer Specialists of North Florida (QCCA), Jacksonville

NOT_YET_RECRUITING

Ocala Oncology, Ocala

NOT_YET_RECRUITING

Brooksville

NOT_YET_RECRUITING

Baptist Cancer Center, Memphis

NOT_YET_RECRUITING

Community Health Network, Indianapolis

NOT_YET_RECRUITING

Goshen Health, Goshen

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

NOT_YET_RECRUITING

Sanford Health, Sioux Falls

NOT_YET_RECRUITING

Edward H. Kaplan MD and Associates, Skokie

NOT_YET_RECRUITING

Nebraska Cancer Specialists (QCCA), Omaha

COMPLETED

START (South Texas Accelerated Research Therapeutics, LLC), San Antonio

COMPLETED

Sarah Cannon Research Institute at HealthONE, Denver

NOT_YET_RECRUITING

Memorial Care, Long Beach

NOT_YET_RECRUITING

St. Joseph's Santa Rosa, Santa Rosa

NOT_YET_RECRUITING

Hawaii Cancer Center, Honolulu

NOT_YET_RECRUITING

Northwest Medical Specialists (QCCA), Tacoma

NOT_YET_RECRUITING

Hartford Health Care, Hartford

RECRUITING

Massachusetts General Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

NOT_YET_RECRUITING

Summit Medical Group, Florham Park